Studying T Cells in Blood and Bone Marrow Samples From Patients With Multiple Myeloma
RATIONALE: Studying samples of blood and bone marrow from patients with cancer in the laboratory may help doctors learn more about T cells and plan better treatment for multiple myeloma.
PURPOSE: This research study is looking at T cells in blood and bone marrow samples from patients with multiple myeloma.
Multiple Myeloma and Plasma Cell Neoplasm
Other: flow cytometry
Other: immunoenzyme technique
Other: laboratory biomarker analysis
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||Strategies to Isolate and Expand Myeloma Specific T-cells Using Autologous B Cells as Antigen Presenting Cell B-APC|
- Percentage of Myeloma-specific T Cells ex Vivo Expanded Using Flow Cytometry [ Time Frame: Collection of PBMCs over a period of 9-12 months, and the laboratory component will be performed over another year. ] [ Designated as safety issue: No ]
- Cell Counts of Myeloma-specific T Cells ex Vivo Expanded Before and After CD3/CD28 Stimulation [ Time Frame: Collection of PBMCs over a period of 9-12 months, and the laboratory component will be performed over another year. ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples Without DNA
|Study Start Date:||April 2008|
|Study Completion Date:||September 2012|
|Primary Completion Date:||November 2009 (Final data collection date for primary outcome measure)|
Other: flow cytometry
- To evaluate the feasibility of expanding myeloma-specific T cells using autologous ex vivo expanded B cells loaded with myeloma antigens as antigen-presenting cells (B-APCs) in peripheral blood and bone marrow samples from patients with multiple myeloma.
- To examine the feasibility of selecting and expanding myeloma-specific T cells ex vivo using interferon γ release and CD3/CD28 stimulation.
OUTLINE: Peripheral blood and bone marrow samples are collected periodically for laboratory studies. Samples are analyzed to assess the feasibility of expanding autologous B cells ex vivo using CD40L and IL-4; the antigen-presenting phenotype of autologous B-cell antigen-presenting cells (B-APCs) using flow cytometry; and the antigen-presenting function of B-APCs using ELISPOT and chromium-release assay. Myeloma-specific interferon γ secreting T cells are isolated and selected using Miltenyi beads. The selected myeloma-specific T cells are expanded ex vivo using anti CD3/CD28 beads.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00897910
|United States, Michigan|
|Barbara Ann Karmanos Cancer Institute|
|Detroit, Michigan, United States, 48201-1379|
|Principal Investigator:||Zaid Al-Kadhimi, MD||Barbara Ann Karmanos Cancer Institute|